Hepatitis B vaccine knowledge and self-reported vaccination status among healthcare workers in a conflict region in northeastern Nigeria

Farouq Muhammad Dayyab[®], Garba Iliyasu, Bashir Garba Ahmad, Abdulaziz Tijjani Bako, Sepu Saraya Ngamariju and Abdulrazaq Garba Habib

Abstract

Background Hepatitis B virus (HBV) infection is highly endemic in Nigeria. The primary objective of this study is to describe the knowledge, self-reported vaccination status, and intention of healthcare workers to receive hepatitis B vaccine at a tertiary referral center in conflict-ravaged northeastern Nigeria.

Methods This was cross-sectional analytical study among medical practitioners, nurses, laboratory workers, health attendants, pharmacists, and radiographers working at Federal Medical Center Nguru, Yobe State. Written informed consent was obtained from all study participants. Data were obtained using questionnaires and entered into a Microsoft Excel spreadsheet, cleaned and analyzed using JMP Pro software.

Results Of the 182 participants, we found that 151 (82.97%), 81 (44.51%), 85 (46.70%), and 33 (18.13%) had good knowledge of HBV, good knowledge of hepatitis B vaccine, were vaccinated against HBV by the least dose, and had a complete hepatitis B vaccination status, respectively. The lack of availability of the vaccine was the main reason for not receiving the vaccine among the unvaccinated 36/91 (39.56%), followed by not knowing where to access the vaccine 19/91 (20.88%).

Conclusion The study highlights the need for strategies to ensure the availability of hepatitis B vaccine in conflict settings and need for vaccinology training given the suboptimal level of awareness and uptake of the hepatitis B vaccine among the healthcare workers.

Keywords: Boko Haram, conflict, healthcare workers, hepatitis B vaccine, hepatitis B virus, infection prevention and control, Nigeria, Yobe State

Received: 29 August 2019; revised manuscript accepted: 19 December 2019.

Introduction

The World Health Organization African region and the western Pacific region are the regions of the world worst hit by the hepatitis B virus (HBV) epidemic.¹ A total of 150 million people were said to be living with chronic HBV infection worldwide in 2015.¹ The estimated population prevalence of chronic HBV infection in Nigeria is high and adds to the urgency of protecting healthcare workers who provide clinical care.² Moreover, 90% of the global occupational exposure to bloodborne pathogens occur in resource-limited countries with 66,000 HBV infections each year worldwide.^{3,4} Abubakar and colleagues reported that 8.7% of the source of occupational exposure to body fluids were positive to hepatitis B surface antigen at a tertiary referral center in Nigeria.⁵ Therefore, improving hepatitis B vaccine coverage of healthcare workers in sub-Saharan Africa is an important public health issue; studies that document

Original Manuscript

Therapeutic Advances in Vaccines and Immunotherapy

2020, Vol. 8: 1–11

DOI: 10.1177/ 2515135519900743

© The Author(s), 2020. Article reuse guidelines: sagepub.com/journalspermissions

Correspondence to: Farouq Muhammad Dayyab

Department of Medicine, Aminu Kano Teaching Hospital, Hospital Road, Kano 3452, Nigeria **farouqmuhd@yahoo.com**

Garba Iliyasu

Abdulrazaq Garba Habib Department of Medicine, Bayero University Kano, Kano, Nigeria

Bashir Garba Ahmad

Department of Medicine, Aminu Kano Teaching Hospital, Kano, Nigeria

Muhammad Abdullahi Wase Teaching Hospital, Kano, Nigeria

Abdulaziz Tijjani Bako Indiana University–Purdue University Indianapolis, IN, USA

Sepu Saraya Ngamariju Department of Medicine, Federal Medical Center Nguru, Nigeria

journals.sagepub.com/home/tav



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

barriers and facilitators to full coverage in specific settings are a critical element of this effort.

Hepatitis B vaccine is highly immunogenic with 90–100% protection conferred following a completed hepatitis B vaccination schedule among infants, children, and adults.⁶

The majority of operating room personnel are aware of the hepatitis B vaccine in Nigeria,⁷ but only 26.8% of them were vaccinated against HBV in Nigeria.⁷ The story is not different in the Republic of Georgia where only 12% of healthcare workers were vaccinated.⁸ In the United States, the hepatitis B vaccination coverage among healthcare workers was 69.5%.⁹ It is noticeable that these vaccination coverages are well below the Healthy People 2010 goal of 90%.⁹

Previous studies have suggested policies and interventions to address the healthcare needs of people affected by conflict.^{10,11} In areas of conflict, the supply of drugs and vaccines is halted, health infrastructure is often destroyed, and health professionals may flee.¹² In addition, health facilities are flooded with multiply injured patients making the immune protection of the healthcare worker from occupational exposure to blood and blood-borne pathogens a cause for concern. Researchers are therefore encouraged to advocate for, and conduct relevant surveys within, settings afflicted by conflicts.¹³

Few studies determine the knowledge, practice, and intention of healthcare workers to receive hepatitis B vaccine in Nigeria, making it challenging to mount prevention and control programs among this high-risk group working in conflict areas. The main objective of this study is to describe the knowledge, self-reported vaccination status and intention of healthcare workers to receive hepatitis B vaccine at a tertiary referral center in conflict-savaged northeastern Nigeria.

Methods

Ethics approval

Ethics approval to conduct the study was obtained from the ethical committee of the Federal Medical Center, Nguru (approval number 30/05/2017-05/06/2017). The ethical committee was certified by the Nigerian National Health Research Ethics Committee. Written informed consent was obtained from all study participants. The authors complied with all ethical regulations.

Study design

This cross-sectional analytical study took place between 21 June and 30 July 2017 among healthcare workers of the Federal Medical Center, Nguru.

Study setting and site

The study was undertaken among healthcare workers at the Federal Medical Center, Nguru, Yobe State, a tertiary referral hospital in northeastern Nigeria. The hospital is situated in a semiurban metropolis located in northeastern Nigeria, ravaged by conflict since August 2011.14 The Boko Haram insurgency is characterized by the use of crude weapons to terrorize and kill security agents and members of the public, as well as kidnappings and use of women and children as suicide bombers in markets, motor parks, places of worship, schools, hospitals, and security posts.¹⁵ Healthcare workers have been killed, abducted, or displaced due to the Boko Haram insurgency.^{15,16} Yobe State was declared a state of emergency during peak periods of the attacks.¹⁶ A reduction in access to healthcare and immunization has been reported in areas afflicted by the Boko Haram insurgency.¹⁷ Additional challenges to the access and functionality of healthcare were posed by counter-insurgency operations, such as banning of motorcycles and temporary interruption of cellphone services during major antiinsurgency operations.16

The hospital has a bed capacity of about 150 and serves as a tertiary referral center in northeastern Nigeria. There is no staff dedicated to infection control and prevention in the hospital. Healthcare workers can access hepatitis B immunization services free of charge at the routine immunization clinic, where hepatitis B vaccine is provided to children under 5 years of age. It is not mandatory for healthcare workers to receive hepatitis B vaccine as part of workplace safety in Nigeria.

Study participants

Study participants comprised hospital workers having direct contact with patients, that is,

medical practitioners, nurses, laboratory workers, health attendants, pharmacists, and radiographers working at the hospital. Single-population proportion formula was used to determine the sample size for this study. We considered a 95% level of confidence, a 5% error margin, and proportion of healthcare workers who were aware of hepatitis B vaccine 86.6%,⁷ to arrive at the required sample size for the study. Eligible study participants were selected using a simple random sampling technique. The sampling frame comprised a list of healthcare workers obtained from the human resource development office of the hospital.

Data collection

Data were collected from respondents using a self-administered standardized questionnaire developed from questionnaire used in a previous study.¹⁸ Hard copies of the questionnaires, provided in English language, were distributed to study participants by research assistants. The purpose of the study was explained, and written consent obtained from the study participants. The participants had an opportunity to contact the research team for clarity on the questions in the questionnaire if the need arose. The questionnaires were completed and returned within an hour or by the end of the working day. Ouestionnaires were coded with numbers and did not have any personal identification to maintain privacy and confidentiality. The questionnaire was pretested on 10 healthcare workers selected randomly, and after that, validated and modified, as appropriate.

There were multiple sections in the questionnaire that covered: demographic characteristics of study participants; knowledge of HBV and hepatitis B vaccine; the practice of hepatitis B vaccination and stated intention to receive the vaccine among the unvaccinated. Only closed-ended questions were included in the questionnaire.

Scoring

Scores of 1 or 2 and 0 were applied to correct and wrong responses, respectively, for graded questions. The section on sociodemographic information was not graded/scored. Knowledge on HBV, knowledge on hepatitis B vaccine and selfreported hepatitis B vaccination status scores for each study participant were obtained out of a possible maximum of 8, 24 and 3, respectively. Scores of \geq 7 and \geq 17 were considered good for knowledge on HBV and knowledge on hepatitis B vaccine, respectively, based on the distribution of respondent scores that was higher than the mean score. Respondents that received at least three shots of hepatitis B vaccine were considered to have complete hepatitis B vaccination status.

Statistical analysis

The data from the questionnaires were entered into a Microsoft Excel (Version 2013; Microsoft Corporation, Redmond, WA, USA) spreadsheet and cleaned. Data from the Excel spreadsheet were then exported to, and analyzed using, JMP Pro software (JMP Version 12.0.1, SAS Institute Inc., Cary, NC, USA). Using descriptive statistics, results were presented as frequencies and percentages. Odds ratios and 95% confidence intervals (CIs) were computed to describe predictors of good knowledge and good practice. Relative risks (RRs) and 95% CIs were computed to describe factors associated with the intention to receive the hepatitis B vaccine among the unvaccinated.

Results

Study population and demographic characteristics

Out of 232 questionnaires distributed, 50 were excluded due to missing data (32) or nonresponses (18). As shown in Table 1, out of the 182 participants, 135 (74%) were males, 148 (81%) were married, 42 (23%) were medical practitioners and 115 (63%) had 0–9 years of service. The median age of the respondents was 34 years. There were 39 (21%), 102 (56%), 28 (15%) and 13 (7%) respondents in the \leq 29 years, 30–39 years, 40–49 years and 50 years or older age groups, respectively.

Knowledge of HBV infection

As shown in Table 1, out of 182 respondents, 151 (82.97%) had good knowledge of HBV. This finding does not differ across age groups, sex, healthcare category, and years of practice. As shown in Table 2, the majority of respondents correctly identified that hepatitis B disease is

Math Regnometries	Variable	Respondents (<i>n</i>)	Good knowledg virus	je of hepatitis B	Good knowledg vaccine	e of hepatitis B	Vaccinated at le	ast once	Complete self- B vaccination s	reported hepatitis tatus
			Respondents, <i>n</i> (%)	0R (95% CI)	Respondents, n (%)	OR (95% CI)	Respondents, <i>n</i> [%]	OR (95% CI)	Respondents, <i>n</i> (%)	OR (95% CI)
Important in the second of the second	Overall	182	151 (82.96)		81 (44.51)		85 (46.70)		33 (18.13)	
Age Sequency Sequency <th< td=""><td>Demographic</td><td>characteristics</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	Demographic	characteristics								
< 29 39 297343 $087(1,3-55)$ $20(12,-35)$ $20(17,-35)$	Age									
-09 102 87 (96.24) 1.4 (1.03.4.6.51) 4 (4.1.4) 2.33 (0.27-1.1.7) 4 (4.6.16) 0.99 (0.31-3.2.9) 1 (1.0.8) 1.36 (0.31-3.2.9) 1 (3.0.13) $40-47$ 2 1 <td>≤29</td> <td>39</td> <td>29 [74.36]</td> <td>0.87 (0.17–3.56)</td> <td>20 (51.28)</td> <td>3.50 (0.91–17.47)</td> <td>20 (51.28)</td> <td>1.22 [0.34-4.46]</td> <td>7 [17.95]</td> <td>1.08 [0.16–7.42]</td>	≤29	39	29 [74.36]	0.87 (0.17–3.56)	20 (51.28)	3.50 (0.91–17.47)	20 (51.28)	1.22 [0.34-4.46]	7 [17.95]	1.08 [0.16–7.42]
40-40 26 56 25 64 14 00 12	30-39	102	87 (85.29)	1.74 (0.36-6.51)	44 (43.14)	2.53 (0.72–11.77)	47 (46.08)	0.99 (0.31–3.29)	19 [18.63]	1.36 [0.23-8.17]
joint 13 107(6)/2 10 312.00 10 64.15 10 215.38 10 low 135 11 135 11 1	40-49	28	25 (89.29)	2.5 (0.40-15.64)	14 (50)	3.33 (0.82–17.31)	12 (42.86)	0.87 (0.23–3.36)	5 [17.86]	1.43 [0.18–11.09]
Beta Mate 135 116(85/3) 209(071-4.69) 61(45.19) 61(45.19) 61(45.19) 7 10 16.6(057- Female k7 35(74.47) 1.0 2.09(071-4.69) 61(45.11) 1.12(057-2.19) 27.20) 1.0 1.0 Compation 35(74.47) 10 21(4.610 21(4.640 10 10 10 Physician 35(74.47) 10 21(4.610/6 </td <td>≥50</td> <td>13</td> <td>10 [76.92]</td> <td>1.0</td> <td>3 (23.08)</td> <td>1.0</td> <td>6 [46.15]</td> <td>1.0</td> <td>2 [15.38]</td> <td>1.0</td>	≥50	13	10 [76.92]	1.0	3 (23.08)	1.0	6 [46.15]	1.0	2 [15.38]	1.0
Mate 135 116 (85,93) 209 (0.91-4.6) 1(4.0157-2.19) 64 (4.74.1) 1.12 (0.57-2.19) 27 [20] 1.46 (0.57) Female 47 35 [74,47) 10 20 (4.25.5) 10 21 (4.66) 10 1 12 (0.57-2.19) 21 (20) 10 106 (10) Cerbariant 35 [74,47) 10 20 (4.25.5) 10 21 (4.66) 10 1 12 (0.57-2.19) 21 (20) 10 106 (10) Cerbariant 35 [74,47) 10 20 (4.26.5) 20 (4.26.5) 21 (4.66.5) 21 (4.66.5) 21 (4.66.5) 21 (4.66.5) 21 (4.66.5) 21 (4.66.5) 21 (4.66.5) 21 (4.26.5) 20 (6.12.5) 21 (6.10.5)	Sex									
Female $i 7$ 5174.47 10 2014.25 10 2144.64 10 612.77 10 612.77 10 Ceropation : $i 7 - i 7 - i 7$ $i 10$ $i 12.77$ $i 10$ $i 12.77$ $i 10$ $i 12.77$ $i 10$ <td>Male</td> <td>135</td> <td>116 (85.93)</td> <td>2.09 (0.91-4.69)</td> <td>61 (45.19)</td> <td>1.11 (0.57–2.19)</td> <td>64 [47.41]</td> <td>1.12 [0.57–2.19]</td> <td>27 (20)</td> <td>1.66 [0.57-4.86]</td>	Male	135	116 (85.93)	2.09 (0.91-4.69)	61 (45.19)	1.11 (0.57–2.19)	64 [47.41]	1.12 [0.57–2.19]	27 (20)	1.66 [0.57-4.86]
Comparise Comparise Comparise 0ccupation 43 40 40 373(0,94-18,57) 23 (53.49) 219(0.86-5.78) 29 (67.44) 6.21 (2.31-18,17) 16 (37.21) 308 (0.51-16) Physician 43 20(7302) 373(0,94-18,57) 22 (45.83) 1.01 (0.66-4.16) 25 (52.08) 3.26 (12.31-18,17) 16 (37.21) 308 (0.51-16) Physician 48 39 (81.25) 11 (13.83-3.67) 11 (13.438) 1.01 (10.5-4.16) 25 (52.08) 3.26 (12.31-18,17) 16 (37.01) 100 Physician 32 25 (73.81) 10 (10.5-4.16) 25 (55.08) 3.26 (12.3-4.16) 10 (10.5-	Female	47	35 [74.47]	1.0	20 (42.55)	1.0	21 (44.68)	1.0	6 [12.77]	1.0
Occupation Physician 43 40 (93.02) 3.73 (0.94-18.57) 23 (53.49) 2.19 (0.86-5.78) 29 (67.44) 6.17 (2.31-18.17) 16 (37.21) 3.08 (0.51-10.17) Nurse 48 39 (81.25) 1.21 (0.383-3.57) 22 (45.83) 1.61 (0.65-4.16) 25 (57.20) 6.17 25) 3.09 (0.12-10.10) Laboratory 32 25 (78.13) 1.0 1.1 (34.38) 1.0 1.1 (34.38) 3.26 (1.26-9.09) 6.12 50 3.09 (0.12-10.10) Laboratory 32 25 (78.13) 1.0 1.1 (34.38) 1.0 1.0 1.0 Heith 18 14 1.0 1.1 (34.38) 1.0 1.0 1.0 Undersoned 18 1.1 (77.78) 8 (44.44) 1.53 (0.46-5.04) 8 (125) 0.79 (12-10.10) 2 (6.25) 1.0 Heith 18 1.1 (34.44) 1.53 (0.46-5.04) 8 (44.44) 1.53 (0.46-5.04) 8 (125) 1.0 2 (6.25) 1.0 Others 33 (80.49) 1.16 (3.25-3.55) 18 (4.42) 1.14 (4.44)	Occupational (characteristics								
Physician 43 40 93.02 3.73 $9.94-1.8.7$ 2.19 2.19 $2.967.44$ 6.21 $2.1-18.17$ 16 3.26 $1.237.21$ 3.08 0.51 Nurse 48 39 91.25 1.21 $0.38-3.67$ $22(45.83)$ 1.61 $0.65-4.16$ 25 55 3.26 $1.237-9.09$ 6 12.51 0.79 0.79 Laboratory 32 25 78.13 1.0 11 1.4 1.73 1.61 $0.56-4.16$ 25 55 3.26 $1.25-9.09$ 6 12.51 0.79 0.79 Health 18 1.4 1.7 1.0 $1.134.38$ 1.0 $1.134.38$ 1.0 1.0 1.0 0.79 0.79 0.79 Health 18 1.4 1.7 1.0 $1.731.46.5.04$ $8.127.78$ $8.14.44$ $1.530.46-5.04$ $8.127.78$ 1.0 $0.790.727$ 1.0 Health 18 $0.980.25-4.28$ $8.14.44$ $1.530.46-5.04$ $1.1560.25-3.59$ $1.16.029-4.21$ 0.10 0.10 Uhers 41 $1.777.84$ $1.741.46$ $1.530.46-5.04$ $1.744.46$ $1.350.46-5.04$ 1.00 0.10 Verse of $1.160.36-3.64$ $1.744.46$ $1.560.52-3.59$ $1.843.94$ $1.160.29-4.21$ 0.19 0.19 Verse of $1.160.36-3.64$ $1.744.46$ $1.560.46-5.04$ $1.164.46$ $1.560.47-6.64$ $0.100.46-5.64$ $0.164.46.64$ $1.060.36-3.04$ $1.000.46-5.64$ Verse of </td <td>Occupation</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Occupation									
Nurse 48 39 [81:25] 1:21 [0.38-3.67] 2 [45.83] 1.61 [0.65-4.16] 2 [55.06] 3.26 [1.26-9.09] [12:5] 0.79 [0.12-10] Laboratory 25 78.13] 1.0 11 [34.38] 1.0 8 [25] 1.0 2 [6.25] 1.0 Health 18 25 78.13 1.0 11 [34.38] 1.0 1.53 [0.46-5.04] 8 [25] 1.0 2 [6.25] 1.0 Health 18 14 1.53 [0.46-5.04] 1.53 [0.46-5.04] 8 [25] 1.15 [0.29-4.21] 0.09 1.0 Health 18 0.9 1.16 [0.36-3.44] 1.74 [4.45] 1.53 [0.46-5.04] 1.16 [0.39-4.21] 0.09 1.0 Others 41 0.9 1.16 [0.36-3.44] 1.74 [4.46] 1.35 [0.52-3.59] 18 [4.39] 2.35 [0.87-6.71] 2 [2.19] 2.25 [0.35- Verse 41 0.33 [80.44] 1.74 [4.46] 1.35 [0.52-3.59] 18 [4.39] 2.19 [3.19] 2 [2.19] 2 [2.19] 2 [2.19] 2 [2.19] 2 [2.19] 2 [2.10] 2 [2.19] </td <td>Physician</td> <td>43</td> <td>40 (93.02)</td> <td>3.73 (0.94–18.57)</td> <td>23 [53.49]</td> <td>2.19 (0.86–5.78)</td> <td>29 [67.44]</td> <td>6.21 [2.31–18.17]</td> <td>16 [37.21]</td> <td>3.08 (0.51–18.53)</td>	Physician	43	40 (93.02)	3.73 (0.94–18.57)	23 [53.49]	2.19 (0.86–5.78)	29 [67.44]	6.21 [2.31–18.17]	16 [37.21]	3.08 (0.51–18.53)
	Nurse	48	39 (81.25)	1.21 (0.38–3.67)	22 (45.83)	1.61 [0.65-4.16]	25 [52.08]	3.26 [1.26–9.09]	6 [12.5]	0.79 (0.12–5.17)
Health attendant18 $14 (77.78)$ $0.98 (0.25 - 4.28)$ $8 (44.44)$ $1.53 (0.46 - 5.04)$ $5 (27.78)$ $1.15 (0.29 - 4.21)$ $0 (0)$ $-$ attendant attendant 41 $33 (80.49)$ $1.16 (0.36 - 3.64)$ $17 (41.46)$ $1.35 (0.52 - 3.59)$ $18 (43.9)$ $2.35 (0.87 - 6.71)$ $9 (21.95)$ $2.25 (0.35 - 3.56)$ Others 41 $33 (80.49)$ $1.16 (0.36 - 3.64)$ $17 (41.46)$ $1.35 (0.52 - 3.59)$ $18 (43.9)$ $2.35 (0.87 - 6.71)$ $9 (21.95)$ $2.25 (0.35 - 3.56)$ Vears of service 115 $97 (84.35)$ $1.79 (0.46 - 5.84)$ $51 (44.35)$ $1.02 (0.36 - 3.04)$ $56 (48.70)$ $1.22 (0.43 - 3.62)$ $22 (19.13)$ $3.88 (0.44 - 3.64)$ $0-9$ 115 $97 (84.35)$ $1.79 (0.46 - 5.84)$ $51 (44.35)$ $1.02 (0.36 - 3.04)$ $56 (48.70)$ $1.22 (0.43 - 3.62)$ $22 (19.13)$ $3.88 (0.44 - 3.64)$ $0-9$ 115 $97 (84.35)$ $1.79 (0.45 - 5.84)$ $1.02 (0.36 - 3.04)$ $56 (4.8.70)$ $1.22 (0.43 - 3.62)$ $22 (19.13)$ $3.88 (0.44 - 3.64)$ $0-9$ $10 - 19$ $10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -$	Laboratory personnel	32	25 [78.13]	1.0	11 (34.38)	1.0	8 (25)	1.0	2 (6.25)	1.0
Others 41 33 (80.4) 1.16 (0.36-3.64) 17 (41.46) 1.35 (0.52-3.59) 18 (43.9) 2.35 (0.87-6.71) 9 (21.95) 2.25 (0.35- Years of service 1	Health attendant	18	14 [77.78]	0.98 (0.25-4.28)	8 (44.44)	1.53 [0.46–5.04]	5 (27.78)	1.15 (0.29–4.21)	(0) 0	1
Vears of service 0-9 115 97 (84.35) 1.79 (0.46-5.84) 51 (44.35) 1.02 (0.36-3.04) 56 (48.70) 1.22 (0.43-3.62) 22 (19.13) 3.88 (0.44- 10-19 51 42 (82.35) 1.55 (0.37-5.75) 23 (45.10) 1.06 (0.36-3.04) 56 (48.70) 1.22 (0.43-3.62) 22 (19.13) 3.88 (0.44- 10-19 51 42 (82.35) 1.55 (0.37-5.75) 23 (45.10) 1.06 (0.36-3.04) 56 (43.14) 0.98 (0.31-3.12) 10 (19.61) 5 (0.51-48) ≥20 16 12 (75.00) 1.0 7 (43.75) 1.0 7 (43.75) 1.0 1 (6.25) 1.0	Others	41	33 (80.49)	1.16 [0.36–3.64]	17 (41.46)	1.35 (0.52–3.59)	18 (43.9)	2.35 (0.87-6.71)	9 (21.95)	2.25 (0.35–14.61)
0-9 115 97 (84.35) 1.79 (0.46-5.84) 51 (44.35) 1.02 (0.36-3.04) 56 (48.70) 1.22 (0.43-3.62) 22 (19.13) 3.88 (0.44-5.84) 10-19 51 42 (82.35) 1.55 (0.37-5.75) 23 (45.10) 1.06 (0.36-3.04) 22 (43.14) 0.98 (0.31-3.12) 10 (19.61) 5 (0.51-48) ≥20 16 12 (75.00) 1.0 7 (43.75) 1.0 7 (43.75) 1.0 1 (6.25) 1.0	Years of service									
10-19 51 42 (82.35) 1.55 (0.37-5.75) 23 (45.10) 1.06 (0.36-3.04) 22 (43.14) 0.98 (0.31-3.12) 10 (19.61) 5 (0.51-48.10) ≥20 16 12 (75.00) 1.0 7 (43.75) 1.0 7 (43.75) 1.0 1 (6.25) 1.0	6-0	115	97 [84.35]	1.79 [0.46–5.84]	51 (44.35)	1.02 (0.36–3.04)	56 [48.70]	1.22 [0.43–3.62]	22 (19.13)	3.88 [0.44-38.48]
≥20 16 12 [75.00] 1.0 7 [43.75] 1.0 7 [43.75] 1.0 1 [6.25] 1.0	10-19	51	42 [82.35]	1.55 (0.37–5.75)	23 (45.10)	1.06 [0.36-3.04]	22 (43.14)	0.98 (0.31–3.12)	10 [19.61]	5 [0.51-48.75]
	≥20	16	12 (75.00)	1.0	7 (43.75)	1.0	7 (43.75)	1.0	1 (6.25)	1.0

Therapeutic Advances in Vaccines and Immunotherapy 8

Table 2. Responses regarding knowledge of hepatitis B virus and hepatitis B vaccine.

Knowledge of hepatitis B virus	Responses, n (%)		
	Yes	Νο	l do not know
Hepatitis B is caused by a virus (<i>n</i> = 178)	171 (96.07)	6 (3.37)	1 (0.56)
Hepatitis B causes liver disease (<i>n</i> = 177)	167 (94.35)	7 (3.95)	3 (1.69)
Hepatitis B can be transmitted through blood, needle prick, sexual activity (<i>n</i> = 178)	169 (94.94)	8 (4.49)	1 (0.56)
Hepatitis B can be seen as yellowness of the eyes, weakness of the body and dark urine (<i>n</i> = 178)	169 (94.94)	6 (3.37)	3 (1.69)
Knowledge of hepatitis B vaccine			
An effective vaccine is available to prevent hepatitis B infection (<i>n</i> = 181)	162 (89.50)	9 (4.97)	10 (5.52)
Hepatitis B vaccine is useful for postexposure prophylaxis (<i>n</i> = 182)	99 (54.40)	62 (34.07)	21 (11.54)
Hepatitis B vaccine cannot be used for immune- compromised patients (<i>n</i> = 176)	94 (53.41)	39 (22.16)	43 (24.43)
Hepatitis B vaccine is effective for the treatment of acute hepatitis B infection (<i>n</i> = 174)	50 (28.74)	104 (59.77)	20 (11.49)
Hepatitis B vaccine can prevent hepatitis B infection effectively if given within 48 h after exposure (<i>n</i> = 170)	82 (48.24)	36 (21.18)	52 (30.59)
Healthcare workers should receive hepatitis B vaccine as part of workplace safety (<i>n</i> = 179)	162 (90.50)	14 (7.82)	3 (1.68)
Full immunization in an adult consists of three or more doses of hepatitis B vaccine (<i>n</i> = 178)	140 (78.65)	17 (9.55)	21 (11.80)
A full course of hepatitis B vaccine may give lifelong immunity, but a booster dose is recommended after five years for healthcare workers (<i>n</i> = 175)	101 (57.71)	36 (20.57)	38 (21.71)
Once the full-dose vaccination of hepatitis B has been given, a blood test is not needed to confirm immunity against the hepatitis B virus (<i>n</i> = 179)	50 (27.93)	107 (59.78)	22 (12.29)
A complete course of hepatitis B vaccine provides 100% protection for 90% of adults (<i>n</i> = 178)	115 (64.61)	26 (14.61)	37 (20.79)
The protection offered by a full-dose hepatitis B vaccine lasts for at least 15 years (<i>n</i> = 173)	88 (50.87)	28 (16.18)	57 (32.95)
Hepatitis B vaccine can cause problems when given to immune people (<i>n</i> = 169)	41 (24.26)	90 (53.25)	38 (22.49)

caused by a virus (96.07%), causes liver disease (94.35%), is transmitted through blood, needle prick, sexual activity (94.94%) and presents clinically with yellowness of the eyes, weakness of the body, and dark urine (94.94%).

Knowledge of hepatitis B vaccine and selfreported vaccination status

Of the 182 respondents studied, 81 (44.51%) had good knowledge of hepatitis B vaccine (Table 1). This finding is not statistically different across

The practice of hepatitis B vaccination	Responses, r	n (%)	
	Yes	No	l do not know
Have you received the hepatitis B vaccine before? ($n = 182$)	85 (46.70)	97 (53.30)	-
If no, do you intend to receive it in the future $(n = 97)^*$	76 (78.35)	15 (15.46)	2 (2.06)
If yes, how many shots did you receive? ($n = 85$)			
1	31	-	-
2	21	-	-
3	32	-	-
>3	1	-	-
Occupational exposure and self-reported hepatitis B infection			
Do you have a history of accidental exposure to blood or blood products of patients (<i>n</i> = 175)	103 (58.86)	70 (40.00)	2 (1.14)
Do you always wear gloves while handling blood and blood products (<i>n</i> = 177)	156 (88.14)	21 (11.86)	-
Do you have a history of having hepatitis B disease/positive HBsAg screen? ($n = 177$)	38 (21.47)	138 (77.97)	1 (0.56)
Were you ever screened for HBsAg ($n = 177$)	129 (72.88)	48 (27.12)	-
*Of the participants that had not received the vaccine before $\frac{1}{\sqrt{97}}$ did not res	spond to this que	stion	

Table 3. Practice of hepatitis B vaccination, occupational exposure, and self-reported hepatitis B infection.

*Of the participants that had not received the vaccine before, 4/97 did not respond to this question. HBsAg, hepatitis B surface antigen.

sociodemographic and occupational characteristics of the participants. As shown in Table 2, fewer respondents correctly identified that there is an effective vaccine for the virus (89.50%), that the vaccine is used for postexposure prophylaxis (54.40%), and that the vaccine is highly effective in preventing HBV infection if given within 48h after exposure (48.24%).

Only 85/182 (46.70%) and 33/182 (18.13%) of the respondents were vaccinated against hepatitis B with the at-least a dose and at-least three doses, respectively (Table 3).

Reasons for receiving the vaccine among the vaccinated

The most commonly reported reasons for receiving the hepatitis B vaccine was fear of illness caused by the virus followed by being at risk of infection and the safety and effectiveness of the vaccine (Table 4).

Reasons for not receiving the vaccine among the unvaccinated

As depicted in Table 5, the lack of availability of the vaccine was the main reason for not receiving the vaccine among the unvaccinated 36/91 (39.56%), followed by not knowing from where to get the vaccine 19/91 (20.88%). The majority of the unvaccinated intend to receive the vaccine in the future 76/91 (83.52%). Among the unvaccinated, those that do not intend to receive the vaccine in the future are more likely to report that they are not at risk of getting the infection (RR=6.43, 95% CI: 3.97-10.40) and that god will protect them from getting the infection (RR=2.95, 95% CI: 1.15-7.52) compared with those that intend to receive the vaccine in the future (Table 5).

Occupational exposure and self-reported history of having HBV infection

As shown in Table 3, 103/175 (58.86%), 129/177 (72.88%) and 38/177 (21.47%) of the respondents reported having had an accidental exposure to blood or body fluids of patients, were ever screened for hepatitis B surface antigen (HBsAg), had a history of having hepatitis B disease/positive HBsAg screen, respectively.

Discussion

Our study has shown that majority of respondents have poor knowledge of hepatitis B vaccine and poor hepatitis B vaccination status, despite the majority having good knowledge of the HBV. We

Table 4. Reasons for receiving the hepatitis B vaccineamong those that reported receiving the vaccine.

Reasons for receiving the hepatitis B vaccination (multiple responses included)	Responses
	Yes
Fear of illness	51
l am at risk	45
It is safe and effective	42

have also shown that the most frequent reason for receiving the vaccine was fear of illness caused by the virus and the commonest reasons for not receiving the vaccine was the lack of availability of the vaccine and not knowing from where to access it. Furthermore, the majority of the unvaccinated intend to receive the vaccine in the future.

Knowledge of HBV infection

Similar to our findings, the majority of respondents had good knowledge of HBV infection in studies conducted in northwestern Nigeria,¹⁹ southern Nigeria,^{7,20} and other parts of the world.^{21–23}

Knowledge of hepatitis B vaccine and selfreported vaccination status

Our findings are similar to those in Pakistan²⁴ but differ from those in Cameroon, where the majority of respondents had good knowledge of the hepatitis B vaccine.²⁵ In our study, the majority of respondents were aware of the existence of an effective vaccine to prevent HBV infection and that the vaccine should be given to healthcare workers as part of workplace safety, but few received at-least dose of the hepatitis B vaccine. Although hepatitis B vaccine is part of the expanded program of immunization and national

Table 5. Reasons for not getting the vaccine among the unvaccinated and their intention to receive the vaccinein the future.

Reasons for not getting the vaccine* (multiple responses included)	Do not intend to receive it in the future	Intend to receive it in the future	Relative risk (95% CI)
God will protect me	4/15	6/76	2.95 (1.15–7.52)
I will protect myself	1/15	6/76	0.86 (0.13–5.57)
Not needed	1/15	6/76	0.86 (0.13–5.59)
Not at risk	1/15	0	6.43 (3.97–10.40)
Not interested	1/15	3/76	1.55 (0.27–9.06)
Not available	5/15	31/76	0.76 (0.28–2.05)
Costly	1/15	3/76	1.5 (0.27–9.07)
Don't know where to get it	2/15	17/76	0.58 (0.14-2.36)
*These reasons were listed in the	e questionnaire as options.		

CI, confidence interval.

immunization program in Nigeria, it is not mandatory for healthcare workers to receive the vaccine as part of workplace safety. This may partly be responsible for the poor vaccination status of the majority of respondents in our study and many other previous studies within and outside Nigeria.^{7,9,21,22,25–29}

The poor knowledge of the utility of the vaccine for postexposure prophylaxis, coupled with poor hepatitis B vaccination status among the healthcare workers is a serious concern, and calls for urgent need for infection prevention and control education to guard the safety of the healthcare workers.

Reasons for receiving the vaccine among the vaccinated

We found that the most commonly reported reasons for receiving the hepatitis B vaccine were fear of illness caused by the virus followed by being at risk of infection and the safety and effectiveness of the vaccine. This is similar to findings in the United States, where the decision to accept or reject hepatitis B vaccine was determined by the beliefs of the healthcare providers regarding the safety and efficacy of the hepatitis B vaccine.³⁰ Various studies have used the health-belief model to examine the uptake of vaccination.^{31,32} The internal locus of control refers to the belief in the power of self in the control of disease; the powerful-others locus of control is the belief in the power of others in the control of disease; while the chance locus of control is the belief in the power of chance in the control of disease.^{30,33–35} These beliefs may play a role in acceptance or declining vaccination.

Reasons for not receiving the vaccine among the unvaccinated

We found that lack of availability of the vaccine was the main reported reason for not receiving the vaccination among the unvaccinated, followed by not having the knowledge of where to get the vaccine. These challenges should be urgently addressed, especially given that the majority of the unvaccinated in our study intend to receive the vaccine in the future. The State Ministry of Health changed drug, vaccine, and consumable deliveries to 3 months from the usual 1 month to minimize stockout. However, out-of-stock drugs, vaccines, and consumables occurred in health facilities in Yobe State during peak periods of the insurgency.¹⁶ The demand in health services fluctuates across facilities during peak periods of the insurgency. For instance, it is reported that during the third quarter of 2012, facility-attended deliveries in Nguru rose sharply to 835 deliveries compared with 111 deliveries in the previous quarter.¹⁶ In Damaturu, the numbers declined to 21 deliveries compared with 797 deliveries over the same period.¹⁶ By the second quarter of 2013, Nguru experienced reduced numbers of deliveries to previous levels, while Damaturu experienced a sharp rise.¹⁶ The pattern reversed again by the third quarter of 2013.16 These fluctuations are largely due to immigration of people to areas perceived as safe, depending on where the insurgents intensify their activities at a time.¹⁶ Hepatitis B vaccine stockouts are likely to occur when large, unanticipated deliveries occur that increase demand for vaccines. Other conflict areas are affected differently. In war-torn countries, there is limited space for health interventions, as evidenced by the continued prevalence of polio in countries afflicted by civil unrest.³⁶ In war-torn Syria, up to 90% of pharmaceutical products that the country produced before the conflict has been reduced, leading to a substantial shortage of essential medicines.37

On the other hand, having no knowledge of where to obtain the vaccine, reported by the healthcare workers as a reason for not receiving the vaccine, is a cause for concern. The fact that some of the healthcare workers were not aware that the vaccine could be obtained at the under 5s immunization clinics, when available, signifies a gap in the hospital infection prevention and control program.

We found a statistically significant difference in reporting not been at risk of getting HBV infection among the unvaccinated not intending to receive the vaccine in the future compared with those intending to receive it. However, this finding should be interpreted with caution, given the small absolute difference in counts. The finding that some unvaccinated healthcare workers not intending to receive the vaccine in the future reported reliance on powerful-others locus of control to provide protection against hepatitis B highlights the importance of motivational factors as predictors of health behavior in healthcare planning. This concept was demonstrated among young women whose decision to receive human papilloma vaccine was fourfold greater when they received a strong recommendation for the vaccine *versus* those who did not.³²

Healthcare professionals have a responsibility to understand the challenges of the complex environments in which they work and adapt workable interventions accordingly.¹⁰

Occupational exposure and self-reported HBV infection

Our finding that the majority of respondents reported having had an accidental exposure to blood or body fluids of patients, and that some of the healthcare workers reported having hepatitis B disease/positive HBsAg screen, further buttresses the need for infection-control-program improvement in the health facility, and the need to ensure availability of the hepatitis B vaccine, even in this setting afflicted with conflict. In the interest of prevention and control of nosocomial infections, the 21.5% of healthcare workers who self-reported having a history of HBV infection or an HBsAg-positive test should go for management of HBV infection if they had not been on any treatment regimen following their diagnosis.

The major limitation of this study is the use of the self-report method to assess the uptake of hepatitis B vaccination which is subject to recall bias. Therefore, the assessment of hepatitis B vaccination status should have been confirmed by examining employee health records where they exist and perhaps by measuring the serum anti-HBS antibody titer of the respondents. Hence an elaborate infection prevention and control program that keeps up-to-date confidential employee health records is recommended in Nigeria. Another limitation of the results is the overall small sample size.

Despite these limitations, to the best of our knowledge, our study was the first to describe vaccination-related knowledge and status among healthcare workers specifically in settings most affected by civil conflict in Nigeria. Gaps have been identified in availability and access to hepatitis B vaccine in conflict settings, with resulting poor vaccination status of healthcare workers. This highlights the need for deliberate efforts to counteract the challenges affecting healthcare delivery in conflict settings and the need for vaccinology training given the suboptimal level of awareness and uptake of the hepatitis B vaccine among the healthcare workers.

Acknowledgement

We acknowledge the research assistants that assisted with data collection.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of interest statement

The authors declare that there is no conflict of interest.

ORCID iD

Farouq Muhammad Dayyab D https://orcid.org/ 0000-0001-8920-6483

Reference

- 1. World Health Organization. *Global hepatitis report* 2017. Geneva: World Health Organization, 2017.
- Shepard CW, Simard EP, Finelli L, et al. Hepatitis B virus infection: epidemiology and vaccination. *Epidemiol Rev* 2006; 28: 112–125.
- Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997; 337: 1485–1490.
- Mbaisi EM, Wanzala P and Omolo J. Prevalence and factors associated with percutaneous injuries and splash exposures among health-care workers in a provincial hospital, Kenya, 2010. *Pan Afr Med J* 2013; 14: 10.
- Abubakar S, Iliyasu G, Dayyab FM, et al. Postexposure prophylaxis following occupational exposure to HIV and hepatitis B: an analysis of a 12-year record in a Nigerian tertiary hospital. *J Infect Prev.* Epub ahead of print 17 December 2017. DOI: 10.1177/1757177417746733.
- Andre F. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. *Vaccine* 1990; 8: S74–S78.
- Kesieme EB, Uwakwe K, Irekpita E, et al. Knowledge of hepatitis B vaccine among operating room personnel in Nigeria and their

vaccination status. *Hepat Res Treat* 2011; 2011: 157089.

- 8. Topuridze M, Butsashvili M, Kamkamidze G, et al. Barriers to hepatitis B vaccine coverage among healthcare workers in the Republic of Georgia: an international perspective. *Infect Control Hosp Epidemiol* 2010; 31: 158–164.
- Byrd KK, Lu PJ and Murphy TV. Hepatitis B vaccination coverage among health-care personnel in the United States. *Public Health Rep* 2013; 128: 498–509.
- Spiegel PB, Checchi F, Colombo S, *et al.* Healthcare needs of people affected by conflict: future trends and changing frameworks. *Lancet* 2010; 375: 341–345.
- Tol WA, Song S and Jordans MJ. Annual research review: resilience and mental health in children and adolescents living in areas of armed conflict–a systematic review of findings in lowand middle-income countries. J Child Psychol Psychiatry 2013; 54: 445–460.
- Kruk ME, Freedman LP, Anglin GA, et al. Rebuilding health systems to improve health and promote statebuilding in post-conflict countries: a theoretical framework and research agenda. Soc Sci Med 2010; 70: 89–97.
- Beyrer C, Villar JC, Suwanvanichkij V, *et al.* Neglected diseases, civil conflicts, and the right to health. *Lancet* 2007; 370: 619–627.
- 14. Walker A. *What is Boko Haram?* Washington, DC: US Institute of Peace, 2012.
- 15. Iyekekpolo WO. Boko Haram: understanding the context. *Third World Q* 2016; 37: 2211–2228.
- 16. Ager AK, Lembani M, Mohammed A, et al. Health service resilience in Yobe state, Nigeria in the context of the Boko Haram insurgency: a systems dynamics analysis using group model building. Conflict Health 2015; 9: 30.
- Bigna JJR. Polio eradication efforts in regions of geopolitical strife: the Boko Haram threat to efforts in Sub-Saharan Africa. *Afr Health Sci* 2016; 16: 584–587.
- Abeje G and Azage M. Hepatitis B vaccine knowledge and vaccination status among health care workers of Bahir Dar city administration, northwest Ethiopia: a cross sectional study. *BMC Infect Dis* 2015; 15: 30.
- 19. Hassan M, Awosan K, Nasir S, *et al.* Knowledge, risk perception and hepatitis B vaccination status of healthcare workers in Usmanu Danfodiyo

University Teaching Hospital, Sokoto, Nigeria. *J Public Health Epidemiol* 2016; 8: 53–59.

- Samuel S, Aderibigbe S, Salami T, et al. Health workers knowledge, attitude and behaviour towards hepatitis B infection in southern Nigeria. Int J Med Med Sci 2009; 1: 418–424.
- Habiba SA, Alrashidi GA, Al-Otaibi AE, *et al.* Knowledge, attitude and behavior of health care workers regarding hepatitis B infection in primary health care, Kuwait. *Greener J Med Sci* 2012; 2: 77–83.
- 22. Koria B and Lala M. A study of knowledge, attitude and practice of hepatitis-B infection among the laboratory technicians in the civil hospital, Ahmedabad, Gujarat. *Health Line* 2012; 3: 63–65.
- 23. Foster T, Lee M, McGaw C, *et al.* Knowledge and practice of occupational infection control among healthcare workers in Jamaica. *West Indian Med J* 2010; 59: 147–152.
- 24. Khan N, Ahmed SM, Khalid MM, *et al.* Effect of gender and age on the knowledge, attitude and practice regarding hepatitis B and C and vaccination status of hepatitis B among medical students of Karachi, Pakistan. *J Pak Med Assoc* 2010; 60: 450–455.
- Aroke D, Kadia BM, Anutebeh EN, et al. Awareness and vaccine coverage of hepatitis B among Cameroonian medical students. *Biomed Res Int* 2018; 2018: 3673289.
- Azodo C, Ehizele A, Uche I, et al. Hepatitis-B vaccination status among dental surgeons in Benin City, Nigeria. Ann Med Health Sci Res 2012; 2: 24–28.
- Ibekwe R and Ibeziako N. Hepatitis B vaccination status among health workers in Enugu, Nigeria. *Niger J Clin Pract* 2006; 9: 7–10.
- Izegbu M, Amole O and Ajayi G. Attitudes, perception and practice of workers in laboratories in the colleges of medicine and their teaching hospitals in Lagos State, Nigeria as regards universal precaution measures. *Biomed Res* 2006; 17: 49–54.
- 29. Ziraba AK, Bwogi J, Namale A, *et al.* Seroprevalence and risk factors for hepatitis B virus infection among health care workers in a tertiary hospital in Uganda. *BMC Infect Dis* 2010; 10: 191.
- Bodenheimer HC Jr, Fulton JP and Kramer PD. Acceptance of hepatitis B vaccine among hospital workers. Am J Public Health 1986; 76: 252–255.

- Nexøe J, Kragstrup J and Søgaard J. Decision on influenza vaccination among the elderly: a questionnaire study based on the health belief model and the multidimensional locus of control theory. *Scand J Prim Health Care* 1999; 17: 105–110.
- Rosenthal S, Weiss TW, Zimet GD, et al. Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation. Vaccine 2011; 29: 890–895.
- Levenson H. Multidimensional locus of control in prison inmates. J Appl Soc Psychol 1975; 5: 342–347.

- Levenson H. Multidimensional locus of control in psychiatric patients. J Consult Clin Psychol 1973; 41: 397.
- Levenson H and Miller J. Multidimensional locus of control in sociopolitical activists of conservative and liberal ideologies. *J Pers Soc Psychol* 1976; 33: 199.
- 36. Bush K. Polio, war and peace. *Bull World Health Organ* 2000; 78: 281–282.
- Sharara SL and Kanj SS. War and infectious diseases: challenges of the Syrian civil war. *PLoS Pathog* 2014; 10: e1004438.

Visit SAGE journals online journals.sagepub.com/ home/tav

SAGE journals